delafloxacin - search results

United States - English - NLM (National Library of Medicine)

baxdela- delafloxacin meglumine tablet baxdela- delafloxacin meglumine injection, powder, lyophilized, for solution

melinta therapeutics, llc - delafloxacin meglumine (unii: n7v53u4u4t) (delafloxacin - unii:6315412yvf) - delafloxacin 450 mg - baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (absssi) caused by the following susceptible microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa] and methicillin-susceptible [mssa] isolates), staphylococcus haemolyticus, staphylococcus lugdunensis, streptococcus agalactiae , streptococcus anginosus group (including streptococcus anginosus , streptococcus intermedius , and streptococcus constellatus ), streptococcus pyogenes , enterococcus faecalis , escherichia coli, enterobacter cloacae, klebsiella pneumoniae, and pseudomonas aeruginosa. baxdela is indicated in adults for the treatment of community-acquired bacterial pneumonia (cabp) caused by the following susceptible microorganisms: streptococcus pneumoniae, staphylococcus aureus (methicillin-susceptible [mssa] isolates only), klebsiella pneumoniae , escherichia coli, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae , chlamydia pneumoniae , legione

European Union - English - EMA (European Medicines Agency)

quofenix

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - community-acquired infections - antibacterials for systemic use, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).consideration should be given to official guidance on the appropriate use of antibacterial agents.